Editor's letter

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

Is 'nearshoring', the preference among pharma and biotech to move operations to the domestic markets versus outsourcing abroad, becoming the norm? This month's cover story assesses the various factors influencing this decision for European companies, and how sticky it may prove to be.

Also in this issue, we investigate the expectations of a National Institutes of Health (NIH)-funded trial investigating glucagon-like peptide-1 receptor agonists (GLP- 1RAs) as a treatment for opioid use disorder. An exclusive interview also evaluates the prospect of sponsors and agencies stepping in to fill the funding gap in light of the Trump administration's cuts to the US Agency for International Development (USAID).

Don’t miss our analysts' take on Pfizer ending the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor